

06-13-05

1 fw

Express Mail No. EV 577 672 939 US

INFORMATION
DISCLOSURE STATEMENT
UNDER 37 C.F.R. 81.97

Attorney Docket	UCAL-131CON3
First Named Inventor	PRUSINER, STANLEY B.
Application Number	10/735,140
Confirmation No.	5681
Filing Date	December 12, 2003
Group Art Unit	1616
Examiner Name	

Address to:
Mail Stop

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Title:

"SODIUM DODECYL SULFATE COMPOSITIONS

FOR INACTIVATING PRIONS"

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08. A copy of each listed publication is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

as der	inea in	§1.30.	
\boxtimes	This s	tatemer	nt qualifies under 37 C.F.R. §1.97, subsection (b) because:
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR
		(2)	It is being filed within 3 months of entry of a national stage OR
	\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits

Atty Docket No. UCAL-131CON3 USSN: 10/10/735,140

		of a request for continued examination under § 1.114.	ne filing
		7 C.F.R. §1.97(c). If this statement is being filed after the latest of: months beyond the filing date of a national application; (2) three beyond the date of entry of the national stage as set forth in §1.4 international application; or (3) the mailing date of a first Office a the merits, but before the mailing date of the earlier of a final office under §1.113 or a notice of allowance under §1.311, then:	months 91 in an action on
		certification as specified in §1.97(e) is provided below; or	
		fee of \$180.00 as set forth in §1.17(p) is authorized below, encluded with the payment of other papers filed together with this statement	
	a fina	0. §1.97(d). If this statement is being filed after the mailing date of the entire action under §1.113 or a notice of allowance under §1.311, but of the issue fee, then:	
	A.	certification as specified in §1.97(e) is completed below; and	
	B.	fee of \$180.00 as set forth in §1.17(p) is authorized below, encluded with the payment of other papers filed together with this statement	-
\boxtimes	Copies	of each of the references listed on the attached Form PTO/SB/08 are of	enclosed
	-	of references listed on the attached Form PTO/SB/08 are enclosed laTHAT:	nerewith
		review of the voluminous nature of references, and the likelihood the eferences are available to the Examiner in the file history of the explication (Serial No. 10/056,222), copies are not enclosed herewith.	
		If any of the foregoing publications are not available to the Examiner's reques	
		opies of only foreign patent documents and non-patent literature are encocordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. oplication publication listed on the attached Form PTO-1449 are not excause this U.S. patent application was filed after June 30, 2003 atternational application has entered the national stage under 35 USC §3 and 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(s. patent enclosed or this 371 after
	There	e no listed references which are not in the English language.	
	The re	vance of those listed references which are not in the English langua	ge is as

	Attached are copies of search report(s) from corresponding patent application(s), submitted in accordance with MPEP 609 D in support of the attached certification under 37 CFR 1.97(e)(1).
	Attached are the following non-published pending patent applications which may be deemed relevant.
	The Commissioner is hereby authorized to charge any underpayment of fees associated his communication, including any necessary fees for extensions of time, or credit any syment to Deposit Account No. 50-0815, order number UCAL-131CON3.
	Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP
1900 U East Pa Telepho	By: Karl Bozicevic Registration No. 28,807 Vic, Field & Francis, LLP Iniversity Avenue, Suite 200 Ilo Alto, California 94303 one: (650) 327-3400 ile: (650) 327-3231

TO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Judget the pacety ork Reduction of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Under the party ork Reduction 3 of 1995, no persons					s required to respond to a collection of information unless it contains a valid OMB control number				
Substitute for form 1440/RTO									
						December 12, 2003			
EME	NT BY	APP	LICANT	First Named Inventor		PRUSINER, STANLEY B.			
(Use as many sheets as necessary)				Art Unit		1616			
				Examiner Nam	e				
	1	of	2	Attorney Docket Number		UCAL-	131CON3		
			U.S. PA	ATENT DOC	UMENTS				
Cite		Docum	ent Number	Publication Date			Pages, Columns, Lines, Where		
No.'	Number-Kind Code ² (if known)		MM-DD-YYYY	Applicant of Cited Docume		Relevant Passages or Relevan Figures Appear	evant		
				-			***		
		·							
	1								
	 			-					
								_	
									
	 								
			.,,						
			FOREIGN	PATENT D	OCUMEN	NTS			
Cite No.	Foreign Pa	atent Do	cument	Publication Date MM-DD-YYYY			Pages, Columns, Lines, Where Relevant Passages or	Т ⁶	
	}			04.24.1005			Relevant Figures Appear		
	EP 0 85	58 79	7 A1	08-19-1998	FORESTIE	ER et al.			
					Date Considered				
	Cite No. 1	Cite No.! Foreign P No.! Country Coe WO 97 WO 97	Cite No.! Cite Docum Number-Kin Cite No.! Cite Docum Number-Kin Cite No.! County Code' - Numb WO 97/1440 WO 97/4977 WO 00/1523	RMATION DISCLOSURE EMENT BY APPLICANT See as many sheets as necessary) 1 of 2 U.S. PA Cite Document Number Number-Kind Code ² (if known) FOREIGN Cite Foreign Patent Document	Filing Date Filing Date First Named In Art Unit Examiner Nam I of 2 Attorney Dock U.S. PATENT DOC Cite No. Number-Kind Code ² (if known) FOREIGN PATENT D Cite No. Foreign Patent Document No. Country Code' - Number - Kind Code ² (if known) FOREIGN PATENT D Cite No. Country Code' - Number - Kind Code ² (if known) WO 97/14404 WO 97/49774 WO 00/15239 Filing Date First Named In Art Unit Examiner Nam Publication Date MM-DD-YYYY Are Country Code' - Number' - Kind Code' (if known) WO 97/49774 WO 00/15239 03-23-2000	Application Number Filing Date First Named Inventor Art Unit Examiner Name 1 of 2 Attorney Docket Number U.S. PATENT DOCUMENTS Cite Document Number Number-Kind Code ² (if known) FOREIGN PATENT DOCUMEN Cite No. 1 Foreign Patent Document No. 1 Cite No. 1 Country Code' - Number'-Kind Code ² (if known) FOREIGN PATENT DOCUMEN MM-DD-YYYY Applicant of Cite MM-DD-YYYY Applicant of Cite No. 1 Country Code' - Number'-Kind Code ² (if known) WO 97/14404 WO 97/49774 WO 00/15239 EP 0 858 797 A1 Date	Application Number 10/735, RMATION DISCLOSURE FEMENT BY APPLICANT See as many sheets as necessary) I of 2 Attorney Docket Number UCAL- U.S. PATENT DOCUMENTS Cite No. Number-Kind Code ² (If known) FOREIGN PATENT DOCUMENTS Cite No. Name of Patentee or Applicant of Cited Document MM-DD-YYYY WO 97/14404 WO 97/14404 WO 97/449774 WO 00/15239 EP 0 858 797 A1 Patication Number 10/735, Filing Date Date Application Number 10/735, Filing Date Document Foreign Patent Document Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Do	RMATION DISCLOSURE FEMENT BY APPLICANT se as many sheets as necessary) I of 2 Attomey Docket Number UCAL-131CON3 U.S. PATENT DOCUMENTS Cite Number-Kind Code ² (If known) Number-Kind Code ² (If known) Number-Kind Code ³ (If known) FOREIGN PATENT DOCUMENTS Figures Appear Figures Appear Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Figures Appear Fullification Date MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MO 97/14404 MO 97/49774 12-31-1997 DOLL et al. Date	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

collection of information unless it contains a valid OMB control m

	Under the	paperwor	k Reduc	tion Act of 1995, no	rsons required to respond to a collection of information unless it contains a valid OMB control number Complete if Known					
Substitute for form 1449/PTO INFORMATION DISCLOSURE					Application Numbe		10/735,140			
					Filing Date		December 12, 2003			
STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Invent	or	PRUSINER, STANLEY B.					
			Art Unit	-						
					Examiner Name					
Sheet 2 of 2					Attorney Docket Nu	ımber	UCAL-131CON3			
				NON PATEN	NT LITERATURI	E DOCUME	ENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s						T ²		
					ion, Sterilization, and l GB XP002325193, Ch		fourth Edition)" 1991, tion of Terms, pages 18-			
CASTLE et al., "Effects of Different Methods of Purification on Aggregation of Scrapie Infectivity" J. Gen. Virol 68:225-231 (1987)					on Aggregation of					
		DATABASE EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL: 1998, DEALLER, SF, "Transmissable Spongiform encephalopathy: Current and future therapeutic stragegies" XP002325195, Database Acession no. EMB-1998210862 *abstract* & Reviews in Medical Microbiology 1998, United Kingdom, vol. 9, no. 3, 1998, pages 135-151, ISSN: 0954-139X DATABASE EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 May 1999 (1999-05-01), SEMAN et al., "Prospects for pharmacological treatment of transmissible subactue spongiform encephalopathies" XP002325196, Database accession no. EMB-1999174466 abstract & Revue du Praticien 01 May 1999 France, vol. 49, no. 9, 1 May 1999 (1999-05-01), pages 971-975, ISSN: 0035-2640								
		URMONEIT et al., "Cationic Lipids (Lipofectamine) and Disturbance of Cellular Cholesterol and aSphingomyelin Distribution Modulates Gamma-Secretase Activity Within Amyloid Precursor Protein In Vitro" Prostaglandins & other Lipid Mediators 55:331-343 (1998)								
Examiner Date signature Considered										

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.